All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 750+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Moderna lands European Commission approval for RSV vaccine
Vaccine, respiratory syncytial virus - Read more

Janssen (Johnson & Johnson) scores European Commission approval for Balversa in urothelial carcinoma
Small molecule, urothelial carcinoma, cancer - Read more

GenFleet Therapeutics nabs China NMPA approval Dupert (fulzerasib, GFH925/IBI351) in lung cancer
Small molecule, lung cancer - Read more

Procept BioRobotics’ prostrate surgery systems lands FDA ok
Medical technology, robotic surgery, prostatic hyperplasia, prostate - Read more

THE GOOD
Business Development

SIGA Technologies lands additional $9M tpoxx order from US DOD
Small molecule, antiviral, monkeypox (mpox), smallpox - Read more

THE GOOD
Clinical Trials

Galapagos gets FDA go-ahead for Ph1/2 CAR-T study
Autologous CAR-T cell therapy, lymphoma, cancer - Read more

Arthrosi to present positive Ph2 data for AR882 in gout
Small molecule, gout - Read more

Viatris touts Ph2 data for cenerimod in lupus
Small molecule, lupus erythematosus, autoimmune - Read more

THE GOOD
Earnings & Finances

Eli Lilly leads the big-earners pack with whopping 36% revenue increase in Q2 2024 YoY - Read more

THE GOOD
Fundraises

Tevogen Bio nabs $6M Series C preferred stock investment
Allogeneic T cell therapy, off-the-shelf, infectious disease, cancer - Read more

Openwater announces $100M raised in total funding
Medical device, infrared, diagnostics, cancer - Read more

PRESENTED BY THE UBC SCHOOL OF BIOMEDICAL ENGINEERING
Unlock the Future of Healthcare Innovation

Join us online on Wednesday, September 25th, at 5:30 PM Pacific for an information session about UBC's new Micro-certificate in Innovation Leadership: Medical & Bio-Innovations.

Discover how this transformative program equips you with essential legal, strategic, and practical skills to bridge the gap between scientific breakthroughs and market success.

What to Expect:

• Learn about the unique opportunities this program offers to advance your career.

• Understand how to make a meaningful impact on healthcare.

• Participate in a live Q&A session.

Don’t miss this opportunity—register now to secure your spot!🔗 

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Market Reports

Q2 2024 VC funding into biopharma at highest levels since Q2 2022, though challenges still remain
Venture capital, biopharma investment - Read more

THE GOOD
Partnerships

Novo Nordisk’s Bio Innovation Hub to partner with MBC BioLabs
Company building, incubation, cardiometabolic disease - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Jazz Pharmaceuticals’ Epidiolex oral solution misses primary endpoint in Ph3 Japanese trial
Small molecule, seizures, Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex - Read more

THE BAD
Lawsuits

Johnson & Johnson’s legal team seeks to convince hold-outs for proposed $6.5M talc settlement
Talc, ovarian cancer - Read more

THE BAD
Layoffs

Tome Biosciences confirms financial struggles, cuts 100 jobs
Gene editing, phenylketonuria, autoimmune - Read more

Bayer to lay off 150 employees at consumer health HQ in Basel
Consumer health - Read more

THE BAD
Partnerships

AnGes and Mitsubishi Tanabe Pharma discontinue licensing agreement
Gene therapy, arteriosclerosis obliterans, Buerger’s disease - Read more

THE BAD
Regulatory

Despite an increasing number of CRLs concerning CMC issues, CDER chief says FDA and inspection standards “have not changed”
Biologic manufacturing, chemistry, manufacturing, and controls (CMC), complete response letter (CRL) - Read more [Paywall]

THE BAD
Strategic Plans

AstraZeneca denies any plans related to relocating UK vaccine manufacturing site to the US
Vaccine, manufacturing - Read more

THE UGLY
No Ugly News today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.